Jinyu Bio-technology (600201) Fundamentals 2026 — P/E 119.1x, Revenue Analysis | SniperIQ
Jinyu Bio-technology (600201) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥12.5B, trading at ¥11.30 on the SHH. This SniperIQ fundamentals page covers Jinyu Bio-technology's valuation (P/E 119.1x, P/B 2.4x), profitability (net margin 7.5%), revenue (¥1.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jinyu Bio-technology's market cap?
Jinyu Bio-technology (600201) has a market capitalization of approximately ¥12.5B, trading at ¥11.30 on the SHH. Market cap moves with the live share price.
What is Jinyu Bio-technology's P/E ratio?
Jinyu Bio-technology's trailing twelve-month P/E ratio is 119.1x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jinyu Bio-technology?
Jinyu Bio-technology runs a net profit margin of 7.5%, a gross margin of 53.0%, and an operating margin of 4.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jinyu Bio-technology generate?
Jinyu Bio-technology reported revenue of ¥1.4B for fiscal year 2025, with net income of ¥100M and earnings per share (EPS) of 0.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jinyu Bio-technology pay a dividend?
Jinyu Bio-technology offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jinyu Bio-technology financially healthy?
Jinyu Bio-technology carries a debt-to-equity ratio of 0.01x and a current ratio of 3.66x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jinyu Bio-technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jinyu Bio-technology (600201) the key facts are: market cap ¥12.5B, P/E 119.1x, revenue ¥1.4B, 52-week range 7.99-19. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jinyu Bio-technology's full fundamentals live
Get Jinyu Bio-technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.